LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medical College and the University of California, San Diego, two preeminent institutions on the cutting edge of gene therapy research. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates in rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.
For more information, please visit www.lexeotx.com.
Location: United States, New York
Employees: 11-50
Total raised: $180M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
| - | Omega Fund... | omegafunds... |
| 23.01.2021 | Longitude ... | longitudec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.03.2024 | - | $95M | - |
| 07.01.2021 | - | $85M | - |
Mentions in press and media 14
| Date | Title | Description |
| 06.03.2026 | FDA reversals leave investors worrying about the fates of other experimental drugs | The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna’s flu shot before reversing course. Companies have accused the FDA of ... |
| 13.10.2025 | Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics | Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between... |
| 27.05.2025 | Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases | Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participati... |
| 17.03.2024 | Lexeo Therapeutics Closes $95M Financing | Lexeo Therapeutics, a genetic medicine company, secures $95 million in private placement, extending runway into 2027. Co-led by Braidwell LP and Adage Capital Partners LP, with participation from various investors. Proceeds to fund clinical... |
| 13.03.2024 | Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing | - |
| 13.03.2024 | Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing | Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide As... |
| 03.11.2023 | Lexeo’s IPO Raises $100M for Gene Therapies That Treat the Heart, Protect the Brain | Precision medicine is a term commonly associated with cancer treatment, but Lexeo Therapeutics applies it to gene therapies addressing underlying causes of certain cardiovascular and neurological diseases. Lexeo now has $100 million to supp... |
| 21.11.2022 | The 10 people transforming healthcare, from companies like Moderna, Humana, and Lexeo Therapeutics | Insider Insider's 100 People Transforming Business highlights 100 leaders across 10 industries who are driving unprecedented change and innovation. The healthcare list includes leaders from such organizations as Alnylam Pharmaceuticals, Hum... |
| 09.09.2021 | LEXEO Therapeutics, LLC announced that it has received $100 million in funding from a group of investors | LEXEO Therapeutics, LLC announced that it has received $100,000,000 in a round of funding co-led by new investors, D1 Capital Partners L.P. and Eventide Asset Management, LLC on September 9, 2021. The transaction also included participation... |
| 09.09.2021 | LEXEO Therapeutics Closes $100 Million Series B Financing to Advance Clinical Stage Gene Therapy Pipeline and Enhance Preclinical Footprint | Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical pipeline development in rare cardiovascular dis... |
Show more